ES2116331T3 - Deteccion del contenido en sindecan en los materiales biologicos tales como tejidos o fluidos fisiologicos que indican transformaciones celulares malignas. - Google Patents

Deteccion del contenido en sindecan en los materiales biologicos tales como tejidos o fluidos fisiologicos que indican transformaciones celulares malignas.

Info

Publication number
ES2116331T3
ES2116331T3 ES92901010T ES92901010T ES2116331T3 ES 2116331 T3 ES2116331 T3 ES 2116331T3 ES 92901010 T ES92901010 T ES 92901010T ES 92901010 T ES92901010 T ES 92901010T ES 2116331 T3 ES2116331 T3 ES 2116331T3
Authority
ES
Spain
Prior art keywords
syndecan
content
tissues
detection
biological materials
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES92901010T
Other languages
English (en)
Inventor
Markku Tapani Jalkanen
Pirjo Leena Kyllikki Inki
Jarkko Kirjavainen
Sirpa Marianne Leppa
Sakari Markku Mali
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Biotie Therapies Corp
Original Assignee
Biotie Therapies Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=27093707&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ES2116331(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Biotie Therapies Corp filed Critical Biotie Therapies Corp
Application granted granted Critical
Publication of ES2116331T3 publication Critical patent/ES2116331T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57469Immunoassay; Biospecific binding assay; Materials therefor for cancer involving tumor associated glycolinkage, i.e. TAG
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57484Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites
    • G01N33/57488Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites involving compounds identifable in body fluids
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/705Assays involving receptors, cell surface antigens or cell surface determinants

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Cell Biology (AREA)
  • Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Biotechnology (AREA)
  • Oncology (AREA)
  • Food Science & Technology (AREA)
  • Medicinal Chemistry (AREA)
  • Hospice & Palliative Care (AREA)
  • Analytical Chemistry (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • General Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Immobilizing And Processing Of Enzymes And Microorganisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Polysaccharides And Polysaccharide Derivatives (AREA)
  • Investigating Or Analysing Materials By The Use Of Chemical Reactions (AREA)
  • Breeding Of Plants And Reproduction By Means Of Culturing (AREA)
  • Agricultural Chemicals And Associated Chemicals (AREA)
  • Chemical Or Physical Treatment Of Fibers (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Abstract

SE PRESENTA UN METODO PARA DETECTAR UNA TRANSFORMACION POTENCIALMENTE DE TRIMENTAL DE UN ORGANISMO. EL METODO COMPRENDE LA DETERMINACION DE INDICACION DE CONTENIDO DE SIDECAN A PARTIR DE UNA MUESTRA DE MATERIAL BIOLOGICO DEL ORGANISMO, Y LA COMPARACION DEL INDICADOR DE CONTENIDO DE SIDECAN DETERMINADO CON UN INDICADOR DE CONTENIDO DE SIDECAN DE REFERENCIA A PARTIR DE UN MATERIAL BIOLOGICO DE REFERENCIA DEL MISMO TIPO.
ES92901010T 1991-01-15 1991-12-19 Deteccion del contenido en sindecan en los materiales biologicos tales como tejidos o fluidos fisiologicos que indican transformaciones celulares malignas. Expired - Lifetime ES2116331T3 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US64120991A 1991-01-15 1991-01-15
US72133091A 1991-07-01 1991-07-01

Publications (1)

Publication Number Publication Date
ES2116331T3 true ES2116331T3 (es) 1998-07-16

Family

ID=27093707

Family Applications (1)

Application Number Title Priority Date Filing Date
ES92901010T Expired - Lifetime ES2116331T3 (es) 1991-01-15 1991-12-19 Deteccion del contenido en sindecan en los materiales biologicos tales como tejidos o fluidos fisiologicos que indican transformaciones celulares malignas.

Country Status (23)

Country Link
US (1) US5422243A (es)
EP (2) EP0816851A3 (es)
JP (1) JP3103377B2 (es)
KR (1) KR0162670B1 (es)
AT (1) ATE166157T1 (es)
AU (1) AU650936B2 (es)
BG (1) BG61625B1 (es)
CA (1) CA2100077C (es)
CZ (1) CZ282203B6 (es)
DE (1) DE69129417T2 (es)
DK (1) DK0569367T3 (es)
ES (1) ES2116331T3 (es)
FI (1) FI104347B1 (es)
HU (1) HU215778B (es)
IE (2) IE990011A1 (es)
NO (1) NO314604B1 (es)
NZ (1) NZ241273A (es)
PL (1) PL168188B1 (es)
PT (1) PT100008B (es)
RU (1) RU2139540C1 (es)
SK (1) SK281583B6 (es)
WO (1) WO1992013274A1 (es)
ZA (1) ZA92271B (es)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5726058A (en) * 1992-12-01 1998-03-10 Jalkanen; Markku Syndecan stimulation of cellular differentiation
AU687767B2 (en) * 1992-12-01 1998-03-05 Oy Biotie Therapies Ltd Syndecan stimulation of cellular differentiation
US6017727A (en) * 1994-03-07 2000-01-25 Biotie Therapies Ltd. Syndecan enhancer element and syndecan stimulation of cellular differentiation
US5851993A (en) * 1994-06-13 1998-12-22 Biotie Therapies Ltd. Suppression of tumor cell growth by syndecan-1 ectodomain
GB9519490D0 (en) * 1995-09-25 1995-11-29 Melvin William T Use of a cytochrome P450 enzyme in tumour cells as a marker and target
US6385546B1 (en) 1996-11-15 2002-05-07 Rutgers, The University Of New Jersey Stabilizing and destabilizing proteins
WO1999008108A1 (en) * 1997-08-12 1999-02-18 Leadd B.V. Determining the transforming capability of agents
EP1146903A4 (en) * 1998-10-16 2005-02-16 Univ California GLYPICANE FOR THE DETECTION AND TREATMENT OF HUMAN CARCINOMA
US6998232B1 (en) * 1999-09-27 2006-02-14 Quark Biotech, Inc. Methods of diagnosing bladder cancer
WO2001077682A1 (fr) * 2000-04-10 2001-10-18 Institut Bioorganicheskoi Khimii Imeni Akademikov M.M. Shemyakina I Ju. A. Ovchinnikova Rossiisskoi Akademii Nauk Anticorps diriges contre le facteur hldf, procedes de fabrication correspondants, peptides avec des capacites antigeniques et a hydrolyse hk et procede de diagnostic de l'etat anaplasique de cellules humaines
AU2002338431A1 (en) * 2001-04-04 2002-11-05 Quark Biotech, Inc. Sequence characteristics of bladder cancer
KR100694804B1 (ko) * 2005-05-18 2007-03-14 아주대학교산학협력단 작은 헤어핀 rna 분자를 포함하는 자궁 내막암 치료또는 예방용 조성물 및 그를 이용한 자궁 내막암 치료 또는예방 방법
US8347890B2 (en) * 2006-06-19 2013-01-08 Insono Therapeutics, Inc. Automated tissue retention system
US20090220588A1 (en) * 2008-02-21 2009-09-03 Massachusetts Institute Of Technology Simultaneous Delivery of Receptors and/or Co-Receptors for Growth Factor Stability and Activity
GB0803272D0 (en) * 2008-02-22 2008-04-02 Smith & Nephew Ultrasound and tissue repair

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3511199A1 (de) * 1985-03-28 1986-10-02 Hoechst Ag, 6230 Frankfurt Verfahren zur immunologischen bestimmung von heparansulfat-proteoglykan, verfahren zur herstellung bzw. reinigung von dafuer geeignetem heparansulfat-proteoglykan aus basalmembran-haltigen geweben
US4859581A (en) * 1986-03-10 1989-08-22 Board Of Regents, The University Of Texas System Endoglycosidase assay
US4945086A (en) * 1988-05-03 1990-07-31 The Board Of Trustees Of The Leland Stanford Junior University Smooth muscle cell growth inhibitor
JPH02156898A (ja) * 1988-12-08 1990-06-15 Seikagaku Kogyo Co Ltd 抗低密度型ヘパラン硫酸プロテオグリカンモノクローン抗体、それを産生するハイブリドーマおよびこのモノクローン抗体を用いる低密度型ヘパラン硫酸プロテオグリカンの検出方法
WO1990007712A1 (de) * 1988-12-23 1990-07-12 Bissendorf Peptide Gmbh Antigen, assoziiert mit degenerativen erscheinungen des zentralen nervensystems (zns), dagegen gerichtete antikörper sowie verfahren zur diagnose von dysfunktionen des zns
WO1990012033A1 (en) * 1989-03-29 1990-10-18 The Board Of Trustees Of The Leland Stanford Junior University Construction and use of synthetic constructs encoding syndecan
AU2561792A (en) * 1991-09-06 1993-04-05 Children's Medical Center Corporation Cell-type specific heparan sulfate proteoglycans and their uses

Also Published As

Publication number Publication date
IE920107A1 (en) 1992-07-15
SK281583B6 (sk) 2001-05-10
FI933211A0 (fi) 1993-07-15
PT100008B (pt) 1999-06-30
CZ282203B6 (cs) 1997-05-14
HU215778B (hu) 1999-02-01
NO932552D0 (no) 1993-07-14
NZ241273A (en) 1993-10-26
PL168188B1 (pl) 1996-01-31
NO932552L (no) 1993-07-14
KR0162670B1 (ko) 1999-05-01
RU2139540C1 (ru) 1999-10-10
CA2100077C (en) 1999-11-16
CA2100077A1 (en) 1992-07-16
PT100008A (pt) 1993-02-26
NO314604B1 (no) 2003-04-14
IE990011A1 (en) 2000-11-01
EP0816851A3 (en) 2000-08-23
AU9071391A (en) 1992-08-27
DE69129417T2 (de) 1998-11-05
HUT67587A (en) 1995-04-28
EP0816851A2 (en) 1998-01-07
CZ137293A3 (en) 1994-01-19
BG61625B1 (bg) 1998-01-30
AU650936B2 (en) 1994-07-07
SK73893A3 (en) 1993-11-10
ATE166157T1 (de) 1998-05-15
JP3103377B2 (ja) 2000-10-30
FI933211A (fi) 1993-09-15
ZA92271B (en) 1992-10-28
EP0569367B1 (en) 1998-05-13
DK0569367T3 (da) 1998-10-07
US5422243A (en) 1995-06-06
DE69129417D1 (de) 1998-06-18
BG97950A (bg) 1995-02-28
FI104347B (fi) 1999-12-31
WO1992013274A1 (en) 1992-08-06
FI104347B1 (fi) 1999-12-31
HU9302030D0 (en) 1993-11-29
EP0569367A1 (en) 1993-11-18
JPH06504616A (ja) 1994-05-26

Similar Documents

Publication Publication Date Title
ES2116331T3 (es) Deteccion del contenido en sindecan en los materiales biologicos tales como tejidos o fluidos fisiologicos que indican transformaciones celulares malignas.
DE3883895D1 (de) Kartusche mit Sensor.
DE68923720D1 (de) Einrichtung und Gerät für die Detektion von Mikroorganismen.
CA2435550A1 (en) System for monitoring the concentration of analytes in body fluids
CY1115366T1 (el) Δεικτες ογκου
AU1775188A (en) Body fluid sample collection tube composite
DE69230890D1 (de) Bestimmung von nukleären matrixproteinen in flüssigkeiten
SE9602298D0 (sv) Arrangement for analysing body fluids
AU7253491A (en) Disposable diagnostic system
NZ242603A (en) Circulating intercellular adhesion molecule-1 (c-icam-1) assay and kit
ES2155513T3 (es) Ensayo de escrutinio para la deteccion precoz de neoplasia colorrectal.
DE3879009D1 (de) Filtrationseinheit mit druckausgleich.
EP0329458A3 (en) Method and apparatus for the measurement of analyte substances
ATE5496T1 (de) Diagnostisches mittel zum nachweis von bilirubin in koerperfluessigkeiten und verwendung eines dafuer geeigneten reagenzes.
FI905189A0 (fi) Kvalitativ och kvantitativ bestaemning av rasproteiner i kroppsvaetskor och -vaevnader samt klassificering av dessa.
Zöphel et al. Recovery-test or immunoradiometric measurement of anti-thyroglobulinautoantibodies
DE59506853D1 (de) Blutprobenanalysengerät mit Chipkartenspeicher
Muller The Central Collaborative Research Group: An overview.
Koen et al. Methods of Determining Arsenic and Its Compounds in Air, Water, Biomaterials, and Other Environmental Media
IT1254319B (it) Apparecchiatura automatica sia fissa sia da campo per la rilevazione della presenza di sostanze tossiche nelle acque, effettuato attraversol'esame dell'andamento del metabolismo di cellule viventi e metodo relativo.

Legal Events

Date Code Title Description
FG2A Definitive protection

Ref document number: 569367

Country of ref document: ES